First FDA-approved drug for vitiligo is a ‘game changer’ (WTOP.com)

First FDA-approved drug for vitiligo is a ‘game changer’

Vitiligo is an autoimmune condition affecting nearly 2 million Americans. It causes patches of skin to lose color or turn white, and it has no cure. But a new treatment approved by the Food and Drug Administration offers hope.

“The introduction of topical Ruxolitinib is a game changer in the management of vitiligo,” said Dr. Adam Friedman, chair of dermatology at The George Washington University School of Medicine and Health Sciences. “Vitiligo imposes a large burden on patients’ lives and many patients suffer from shame and embarrassment, low self-confidence and social isolation,” he said.

The topical cream takes about six months to work and might not be covered by insurance. 

“It will be an insurance by insurance situation,” Friedman said. “Given this is the only FDA-approved therapy, our hope is that insurance companies will cover it to provide relief for the up to 2% of the population that suffers with this condition.”

 

Read the full article on WTOP.com

Latest News

The GW Medical Faculty Associates is pleased to announce that Steven W. Boyce, MD, will serve as Chief of the Division of Cardiac Surgery. He also serves as a Professor of Surgery. The division, which is part of the larger Department of Surgery, is home to a broad group of nationally and…
Air quality in the Washington, D.C. area is unusually poor, and while it may be invisible some days, the threat is still there. Daniel Baram, MD, associate professor of medicine at the George Washington (GW) School of Medicine and Health Sciences (SMHS) and division Director of Pulmonary Medicine…
The George Washington University (GW) School of Medicine and Health Sciences (SMHS) is pleased to announce the selection of Karen A. Fagan, MD, to serve as the Chair of the GW Department of Medicine.